Molecular imaging of the tumor microenvironment for precision medicine and theranostics

Advances in Cancer Research

Volumn 124, Issue , 2014, Pages 235-256

  Penet, Marie France ^a,b   Krishnamachary, Balaji ^a   Chen, Zhihang ^a   Jin, Jiefu ^a   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Molecular imaging; Precision medicine; Theranostics; Tumor microenvironment

Indexed keywords

SCLEROPROTEIN;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER THERAPY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FLUORESCENCE IMAGING; HUMAN; HYPOXIA; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; MOLECULAR IMAGING; PERSONALIZED MEDICINE; PH; PRECISION MEDICINE AND THERANOSTICS; STROMA CELL; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; MOLECULAR IMAGING; NEOPLASMS; PRECISION MEDICINE; TUMOR MICROENVIRONMENT;

EID: 84907854838     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411638-2.00007-0     Document Type: Chapter

References (69)

1. Anderson S.A., Glod J., Arbab A.S., Noel M., Ashari P., Fine H.A., et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005, 105(1):420-425.
2. Brown E., McKee T., diTomaso E., Pluen A., Seed B., Boucher Y., et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nature Medicine 2003, 9(6):796-800.
3. Carlin S., Zhang H., Reese M., Ramos N.N., Chen Q., Ricketts S.A. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 2014, 55(3):515-521.
4. Chaumeil M.M., Gini B., Yang H., Iwanami A., Sukumar S., Ozawa T., et al. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology 2012, 14(8):1050-1061.
5. Chen L.Q., Howison C.M., Jeffery J.J., Robey I.F., Kuo P.H., Pagel M.D. Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 2013, [Epub ahead of print]. 10.1002/mrm.25053.
6. Chen Z., Penet M.F., Nimmagadda S., Li C., Banerjee S.R., Winnard P.T., et al. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 2012, 6(9):7752-7762.
7. Cittadino E., Ferraretto M., Torres E., Maiocchi A., Crielaard B.J., Lammers T., et al. MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2012, 45(4):436-441.
8. Daldrup-Link H.E., Golovko D., Ruffell B., Denardo D.G., Castaneda R., Ansari C., et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17(17):5695-5704.
9. Daldrup-Link H.E., Meier R., Rudelius M., Piontek G., Piert M., Metz S., et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. European Radiology 2005, 15(1):4-13.
10. Eisenblatter M., Holtke C., Persigehl T., Bremer C. Optical techniques for the molecular imaging of angiogenesis. European Journal of Nuclear Medicine and Molecular Imaging 2010, 37(Suppl. 1):S127-S137.
11. Fu A., Wilson R.J., Smith B.R., Mullenix J., Earhart C., Akin D., et al. Fluorescent magnetic nanoparticles for magnetically enhanced cancer imaging and targeting in living subjects. ACS Nano 2012, 6(8):6862-6869.
12. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry 2007, 101(4):937-949.
13. Gallagher F.A., Kettunen M.I., Day S.E., Hu D.E., Ardenkjaer-Larsen J.H., Zandt R., et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453(7197):940-943.
14. Gao G.H., Li Y., Lee D.S. Environmental pH-sensitive polymeric micelles for cancer diagnosis and targeted therapy. Journal of Controlled Release: Official Journal of the Controlled Release Society 2013, 169(3):180-184.
15. Gillies R.J., Gatenby R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Reviews 2007, 26(2):311-317.
16. Gillies R.J., Raghunand N., Karczmar G.S., Bhujwalla Z.M. MRI of the tumor microenvironment. Journal of Magnetic Resonance Imaging 2002, 16(4):430-450.
17. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. Journal of Nuclear Medicine 2008, 49(Suppl. 2):24S-42S.
18. Grange C., Geninatti-Crich S., Esposito G., Alberti D., Tei L., Bussolati B., et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Research 2010, 70(6):2180-2190.
19. Granot D., Addadi Y., Kalchenko V., Harmelin A., Kunz-Schughart L.A., Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Research 2007, 67(19):9180-9189.
20. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British Journal of Radiology 1953, 26(312):638-648.
21. Gulaka P.K., Rojas-Quijano F., Kovacs Z., Mason R.P., Sherry A.D., Kodibagkar V.D. GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo. Journal of Biological Inorganic Chemistry: JBIC: A Publication of the Society of Biological Inorganic Chemistry 2014, 19(2):271-279.
22. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. The New England Journal of Medicine 2003, 348(25):2491-2499.
23. Harlaar N.J., Kelder W., Sarantopoulos A., Bart J., Themelis G., van Dam G.M., et al. Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3-)integrin targeted agent. Gynecologic Oncology 2013, 128(3):590-595.
24. Hu D.E., Kettunen M.I., Brindle K.M. Monitoring T-lymphocyte trafficking in tumors undergoing immune rejection. Magnetic Resonance in Medicine 2005, 54(6):1473-1479.
25. Iagaru A., Gambhir S.S. Imaging tumor angiogenesis: The road to clinical utility. AJR. American Journal of Roentgenology 2013, 201(2):W183-W191.
26. Jain R.K. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31(17):2205-2218.
27. Kakkad S.M., Penet M.F., Akhbardeh A., Pathak A.P., Solaiyappan M., Raman V., et al. Hypoxic tumor environments exhibit disrupted collagen I fibers and low macromolecular transport. PLoS One 2013, 8(12):e81869.
28. Kakkad S.M., Solaiyappan M., Argani P., Sukumar S., Jacobs L.K., Leibfritz D., et al. Collagen I fiber density increases in lymph node positive breast cancers: Pilot study. Journal of Biomedical Optics 2012, 17(11):116017.
29. Kakkad S.M., Solaiyappan M., O'Rourke B., Stasinopoulos I., Ackerstaff E., Raman V., et al. Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia 2010, 12(8):608-617.
30. Ko J., Park K., Kim Y.S., Kim M.S., Han J.K., Kim K., et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. Journal of Controlled Release: Official Journal of the Controlled Release Society 2007, 123(2):109-115.
31. Kodibagkar V.D., Cui W., Merritt M.E., Mason R.P. Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magnetic Resonance in Medicine 2006, 55(4):743-748.
32. Lee C.P., Payne G.S., Oregioni A., Ruddle R., Tan S., Raynaud F.I., et al. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. British Journal of Cancer 2009, 101(11):1860-1868.
33. Li J., Chen K., Liu H., Cheng K., Yang M., Zhang J., et al. Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. Bioconjugate Chemistry 2012, 23(8):1704-1711.
34. Li Y., Foss C.A., Summerfield D.D., Doyle J.J., Torok C.M., Dietz H.C., et al. Targeting collagen strands by photo-triggered triple-helix hybridization. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(37):14767-14772.
35. Li C., Penet M.F., Wildes F., Takagi T., Chen Z., Winnard P.T., et al. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano 2010, 4(11):6707-6716.
36. Marignol L., Foley R., Southgate T.D., Coffey M., Hollywood D., Lawler M. Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: A highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro. The Journal of Gene Medicine 2009, 11(2):169-179.
37. Mason R.P., Shukla H., Antich P.P. In vivo oxygen tension and temperature: Simultaneous determination using 19F NMR spectroscopy of perfluorocarbon. Magnetic Resonance in Medicine 1993, 29(3):296-302.
38. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nature Medicine 2007, 13(3):372-377.
39. Mitsunaga M., Ogawa M., Kosaka N., Rosenblum L.T., Choyke P.L., Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature Medicine 2011, 17(12):1685-1691.
40. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. Journal of Cellular and Molecular Medicine 2009, 13(9A):2780-2786.
41. Pan D., Pramanik M., Senpan A., Allen J.S., Zhang H., Wickline S.A., et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2011, 25(3):875-882.
42. Pascal J., Bearer E.L., Wang Z., Koay E.J., Curley S.A., Cristini V. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(35):14266-14271.
43. Pathak A.P., McNutt S., Shah T., Wildes F., Raman V., Bhujwalla Z.M. In vivo "MRI phenotyping" reveals changes in extracellular matrix transport and vascularization that mediate VEGF-driven increase in breast cancer metastasis. PLoS One 2013, 8(5):e63146.
44. Pathak A.P., Penet M.F., Bhujwalla Z.M. MR molecular imaging of tumor vasculature and vascular targets. Advances in Genetics 2010, 69:1-30.
45. Procissi D., Claus F., Burgman P., Koziorowski J., Chapman J.D., Thakur S.B., et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clinical Cancer Research 2007, 13(12):3738-3747.
46. Provent P., Benito M., Hiba B., Farion R., Lopez-Larrubia P., Ballesteros P., et al. Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Research 2007, 67(16):7638-7645.
47. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Medicine 2006, 4(1):38.
48. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine 2013, 19(11):1423-1437.
49. Raman V., Artemov D., Pathak A.P., Winnard P.T., McNutt S., Yudina A., et al. Characterizing vascular parameters in hypoxic regions: A combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Research 2006, 66(20):9929-9936.
50. Robey I.F., Baggett B.K., Kirkpatrick N.D., Roe D.J., Dosescu J., Sloane B.F., et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Research 2009, 69(6):2260-2268.
51. Ross R.W., Zietman A.L., Xie W., Coen J.J., Dahl D.M., Shipley W.U., et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clinical Imaging 2009, 33(4):301-305.
52. Schmieder A.H., Caruthers S.D., Zhang H., Williams T.A., Robertson J.D., Wickline S.A., et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2008, 22(12):4179-4189.
53. Schmieder A.H., Winter P.M., Williams T.A., Allen J.S., Hu G., Zhang H., et al. Molecular MR imaging of neovascular progression in the Vx2 tumor with alphavbeta3-targeted paramagnetic nanoparticles. Radiology 2013, 268(2):470-480.
54. Seenu V., Pavan Kumar M.N., Sharma U., Gupta S.D., Mehta S.N., Jagannathan N.R. Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. Magnetic Resonance Imaging 2005, 23(10):1005-1010.
55. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29(5):625-634.
56. Servagi-Vernat S., Differding S., Hanin F.X., Labar D., Bol A., Lee J.A., et al. A prospective clinical study of F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging 2014, 41(8):1544-1552.
57. Shih Y.Y., Hsu Y.H., Duong T.Q., Lin S.S., Chow K.P., Chang C. Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR in Biomedicine 2011, 24(10):1353-1360.
58. Spence A.M., Muzi M., Swanson K.R., O'Sullivan F., Rockhill J.K., Rajendran J.G., et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14(9):2623-2630.
59. Stasinopoulos I., Penet M.F., Chen Z., Kakkad S., Glunde K., Bhujwalla Z.M. Exploiting the tumor microenvironment for theranostic imaging. NMR in Biomedicine 2011, 24(6):636-647.
60. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 1955, 9(4):539-549.
61. Vahrmeijer A.L., Hutteman M., van der Vorst J.R., van de Velde C.J., Frangioni J.V. Image-guided cancer surgery using near-infrared fluorescence. Nature Reviews. Clinical Oncology 2013, 10(9):507-518.
62. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: First in-human results. Nature Medicine 2011, 17(10):1315-1319.
63. 1H MRSI. Magnetic Resonance in Medicine 1999, 41(4):743-750.
64. Vandsburger M.H., Radoul M., Addadi Y., Mpofu S., Cohen B., Eilam R., et al. Ovarian carcinoma: Quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors. Radiology 2013, 268(3):790-801.
65. Wang Z., Yu Y., Ma J., Zhang H., Wang X., Wang J., et al. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Molecular Pharmaceutics 2012, 9(9):2646-2657.
66. Wang L., Zhu X., Xie C., Ding N., Weng X., Lu W., et al. Imaging acidosis in tumors using a pH-activated near-infrared fluorescence probe. Chemical Communications 2012, 48(95):11677-11679.
67. Weidle U.H., Tiefenthaler G., Georges G. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genomics & Proteomics 2014, 11(2):67-79.
68. Winter P.M., Schmieder A.H., Caruthers S.D., Keene J.L., Zhang H., Wickline S.A., et al. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2008, 22(8):2758-2767.
69. Yang H., Zou L.G., Zhang S., Gong M.F., Zhang D., Qi Y.Y., et al. Feasibility of MR imaging in evaluating breast cancer lymphangiogenesis using Polyethylene glycol-GoldMag nanoparticles. Clinical Radiology 2013, 68(12):1233-1240.